Optimal Conditions for Lentiviral Transduction of Engrafting Human CD34+ Cells

Overview

Journal Gene Ther

Date 2011 May 6

PMID 21544097

Citations 36

Authors

N Uchida

M M Hsieh

J Hayakawa

C Madison

K N Washington

J F Tisdale

Affiliations

Soon will be listed here.

Abstract

Cytokines are required for γ-retroviral transduction of human CD34+ cells. However, cytokines may reduce engraftment of CD34+ cells and may not be necessary for their lentiviral transduction. We sought to optimize transduction and engraftment of human CD34+ cells using lentiviral vectors. Single 24 h transduction of human CD34+ cells with human immunodeficiency virus type 1 (HIV1)-based lentiviral vectors in media containing stem cell factor (SCF), FMS-like tyrosine kinase 3 (FLT3) ligand, thrombopoietin (each 100 ng ml⁻¹) and 10% fetal bovine serum was compared with various cytokine conditions during ex vivo culture and assayed using humanized xenograft mice for 6 months after transplantation. Serum-free media improved transduction efficiency of human CD34+ cells. Interleukin-3 (20 ng ml⁻¹) had little effect on transduction efficiency or engraftment. Threefold higher cytokine mixture (each 300 ng ml⁻¹) reduced engraftment of CD34+ cells. SCF alone (100 ng ml⁻¹) proved insufficient for maintaining engraftment ability and reduced transduction efficiency. Short-term prestimulation had little effect on transduction efficiency or engraftment, yet 24 h prestimulation showed higher transduction efficiency, higher gene expression levels and lower engraftment. In summary, 24 h prestimulation followed by single 24-h lentiviral transduction in serum-free media with SCF, FLT3 ligand and thrombopoietin yields high transduction efficiency to engrafting human CD34+ cells, and is applicable in human clinical gene therapy trials.

Citing Articles

Post-transplant G-CSF impedes engraftment of gene-edited human hematopoietic stem cells by exacerbating p53-mediated DNA damage response.

Araki D, Chen V, Redekar N, Salisbury-Ruf C, Luo Y, Liu P Cell Stem Cell. 2024; 32(1):53-70.e8.

PMID: 39536761 PMC: 11698648. DOI: 10.1016/j.stem.2024.10.013.

Advances in HIV Gene Therapy.

Kitawi R, Ledger S, Kelleher A, Ahlenstiel C Int J Mol Sci. 2024; 25(5).

PMID: 38474018 PMC: 10931721. DOI: 10.3390/ijms25052771.

TGF Inhibitor A83-01 Enhances Murine HSPC Expansion for Gene Therapy.

Fleischauer J, Bastone A, Selich A, John-Neek P, Weisskoeppel L, Schaudien D Cells. 2023; 12(15).

PMID: 37566057 PMC: 10416825. DOI: 10.3390/cells12151978.

A novel preclinical model of mucopolysaccharidosis type II for developing human hematopoietic stem cell gene therapy.

Shimada Y, Ishii N, Higuchi T, Goto M, Ohashi T, Kobayashi H Gene Ther. 2022; 30(3-4):288-296.

PMID: 35835952 DOI: 10.1038/s41434-022-00357-y.

Hematopoietic Stem Cell Gene-Addition/Editing Therapy in Sickle Cell Disease.

Germino-Watnick P, Hinds M, Le A, Chu R, Liu X, Uchida N Cells. 2022; 11(11).

PMID: 35681538 PMC: 9180595. DOI: 10.3390/cells11111843.

References

Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L . Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med. 2009; 360(5):447-58. DOI: 10.1056/NEJMoa0805817. View

Kiem H, Andrews R, Morris J, Peterson L, Heyward S, Allen J . Improved gene transfer into baboon marrow repopulating cells using recombinant human fibronectin fragment CH-296 in combination with interleukin-6, stem cell factor, FLT-3 ligand, and megakaryocyte growth and development factor. Blood. 1998; 92(6):1878-86. View

Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K . NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002; 100(9):3175-82. DOI: 10.1182/blood-2001-12-0207. View

Vigna E, Naldini L . Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med. 2000; 2(5):308-16. DOI: 10.1002/1521-2254(200009/10)2:5<308::AID-JGM131>3.0.CO;2-3. View

Abonour R, Williams D, Einhorn L, Hall K, Chen J, Coffman J . Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med. 2000; 6(6):652-8. DOI: 10.1038/76225. View

Williams D, Rios M, Stephens C, Patel V . Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature. 1991; 352(6334):438-41. DOI: 10.1038/352438a0. View

Dunbar C . Gene transfer to hematopoietic stem cells: implications for gene therapy of human disease. Annu Rev Med. 1996; 47:11-20. DOI: 10.1146/annurev.med.47.1.11. View

Cavazzana-Calvo M, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F . Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000; 288(5466):669-72. DOI: 10.1126/science.288.5466.669. View

Piacibello W, Gammaitoni L, Bruno S, Gunetti M, Fagioli F, Cavalloni G . Negative influence of IL3 on the expansion of human cord blood in vivo long-term repopulating stem cells. J Hematother Stem Cell Res. 2001; 9(6):945-56. DOI: 10.1089/152581600750062408. View

10.

Rivella S, May C, Chadburn A, Riviere I, Sadelain M . A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood. 2002; 101(8):2932-9. DOI: 10.1182/blood-2002-10-3305. View

11.

Geronimi F, Richard E, Redonnet-Vernhet I, Lamrissi-Garcia I, Lalanne M, Ged C . Highly efficient lentiviral gene transfer in CD34+ and CD34+/38-/lin- cells from mobilized peripheral blood after cytokine prestimulation. Stem Cells. 2003; 21(4):472-80. DOI: 10.1634/stemcells.21-4-472. View

12.

Zandstra P, Conneally E, Petzer A, Piret J, Eaves C . Cytokine manipulation of primitive human hematopoietic cell self-renewal. Proc Natl Acad Sci U S A. 1997; 94(9):4698-703. PMC: 20787. DOI: 10.1073/pnas.94.9.4698. View

13.

Millington M, Arndt A, Boyd M, Applegate T, Shen S . Towards a clinically relevant lentiviral transduction protocol for primary human CD34 hematopoietic stem/progenitor cells. PLoS One. 2009; 4(7):e6461. PMC: 2714083. DOI: 10.1371/journal.pone.0006461. View

14.

Imren S, Payen E, Westerman K, Pawliuk R, Fabry M, Eaves C . Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A. 2002; 99(22):14380-5. PMC: 137892. DOI: 10.1073/pnas.212507099. View

15.

Dunbar C, Takatoku M, Donahue R . The impact of ex vivo cytokine stimulation on engraftment of primitive hematopoietic cells in a non-human primate model. Ann N Y Acad Sci. 2001; 938:236-44; discussion 244-5. DOI: 10.1111/j.1749-6632.2001.tb03594.x. View

16.

Yonemura Y, Ku H, Hirayama F, Souza L, Ogawa M . Interleukin 3 or interleukin 1 abrogates the reconstituting ability of hematopoietic stem cells. Proc Natl Acad Sci U S A. 1996; 93(9):4040-4. PMC: 39483. DOI: 10.1073/pnas.93.9.4040. View

17.

Sellers S, Tisdale J, Agricola B, Donahue R, Dunbar C . The presence of the carboxy-terminal fragment of fibronectin allows maintenance of non-human primate long-term hematopoietic repopulating cells during extended ex vivo culture and transduction. Exp Hematol. 2004; 32(2):163-70. DOI: 10.1016/j.exphem.2003.10.003. View

18.

Bukrinsky M, Haggerty S, Dempsey M, Sharova N, Adzhubel A, Spitz L . A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature. 1993; 365(6447):666-9. PMC: 9524217. DOI: 10.1038/365666a0. View

19.

Roesler J, Brenner S, Bukovsky A, Whiting-Theobald N, Dull T, Kelly M . Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood. 2002; 100(13):4381-90. DOI: 10.1182/blood-2001-12-0165. View

20.

Malim M . APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci. 2008; 364(1517):675-87. PMC: 2660912. DOI: 10.1098/rstb.2008.0185. View